Hatemi et al reported that an increase of PR3-ANCA titer may help to predict relapses in ANCA-associated vasculitis patients and PR3-ANCA may also be associated with better response to rituximab [6]. The gene discussed is PRTN3; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.